In an update shared via webcast on June 27, the company reported better overall survival in patients with a time to progression less than three years from transplant who were treated with Pepaxti plus dexamethasone than in those on Pomalyst plus dexamethasone (median survival time of 23.6 vs. 19.8 months). This difference, however, was not significant.